The state’s Community Organized Relief Effort was able to go from zero field teams to 36 in just 60 days. The Community Organized Relief Effort in Georgia, better known as CORE, had a major operational challenge to coordinate all the logistical issues of setting up mobile vaccinations for COVID-19 across an entire state and managing dozens…Read More
AdvaMed, the world’s leading trade association for medical technology companies—which includes the diagnostics companies that make Covid-19 tests—released the following statement from president and CEO Scott Whitaker: “We applaud the President and his Administration for recognizing the critical roles regular testing and widespread vaccination serve in bringing the pandemic under control. We look forward to continuing…Read More
French drug maker Sanofi said Wednesday that it will acquire Kadmon Pharmaceuticals for $1.9 billion, bolstering its transplant medicines business with a newly approved treatment for graft-versus-host disease. The all-cash transaction sees Kadmon shares worth $9.50 per share, or a 79% premium to Tuesday’s closing price. In July, Kadmon secured U.S. approval for Rezurock, a new treatment…Read More
Moderna will turn to a biotech startup, National Resilience, to manufacture additional doses of its Covid-19 vaccine. Moderna had previously said it would manufacture 800 million to 1 billion doses of its Covid-19 vaccine in 2021, ramping up to 3 billion doses in 2022. A person familiar with the company said the collaboration might result in hundreds of…Read More
A University of Georgia lab in Tifton was recognized in August for its efforts to expand the number of underrepresented, first-generation and rural students who choose careers in science, technology, math and engineering. The exploratory academy at the University of Georgia’s Tifton Veterinary Diagnostic & Investigational Laboratory received a 2021 Inspiring Programs in STEM award from Insight into Diversity, the oldest…Read More
CyanVac LLC of Athens, Georgia, a small pharmaceutical manufacturing company founded in 2017, developed a vaccine that’s about to be tested.
CVXGA1 employs a live vector virus that hasn’t been used in humans so far. One squirt per nostril and you’re protected from COVID-19? That’s the intent of a vaccine that’s about to be tested in a clinical trial, which will run at three U.S. research sites including the Gamble Center for Vaccine Research at Cincinnati Children’s…Read More